Overview
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting. Carboplatin was granted FDA approval on 3 March 1989.
Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
Associated Conditions
- Advanced Cervical Cancer
- Advanced Endometrial Cancer
- Advanced Esophageal Cancers
- Advanced Head and Neck Cancer
- Advanced Melanoma
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Advanced Ovarian Carcinoma
- Advanced Sarcoma
- Malignant Pleural Mesothelioma (MPM)
- Merkel Cell Carcinoma
- Metastatic Breast Cancer
- Refractory Hodgkin Lymphoma
- Retinoblastoma
- Thymoma
- Advanced Bladder cancer
- Advanced Small cell lung cancer
- Advanced Testicular cancer
- Advanced Thymoma
- Refractory Non-Hodgkin's lymphoma
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2009/09/09 | Phase 2 | Completed | |||
2009/08/27 | Phase 2 | Completed | |||
2009/08/17 | Phase 2 | Terminated | |||
2009/08/10 | Phase 2 | Terminated | |||
2009/08/07 | Phase 3 | UNKNOWN | GOG Foundation | ||
2009/08/07 | Phase 1 | Terminated | |||
2009/08/06 | Phase 2 | Completed | |||
2009/08/04 | Phase 2 | Withdrawn | |||
2009/08/04 | Phase 3 | Completed | |||
2009/07/30 | Early Phase 1 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.